Literature DB >> 7780644

Differential effects of OPC-18790, amrinone and dobutamine on cardiac function and energy metabolism in the guinea-pig isolated ischaemic heart.

S Itoh1, T Mori, M Tominaga, M Ishikawa, K Koga, Y Yabuuchi.   

Abstract

1. The effects of OPC-18790, a novel positive inotropic agent, on cardiac function and myocardial energy metabolism in the guinea-pig isolated heart with ischaemia were studied by 31P-magnetic resonance spectroscopy (MRS) and compared with those of amrinone and dobutamine. 2. Cardiac ischaemia was induced by intracoronary infusion of 15 microns microspheres to reduce coronary perfusion flow (CPF) by 50%. Microsphere embolisation caused a 40% decrease in left ventricular systolic pressure (LVSP), cardiac contractility measured by peak of ventricular pressure development (LVdP/dt) and slightly reduced heart rate. There was also a decrease in ATP and creatine phosphate (PCr) by 20%, an increase in inorganic phosphate (Pi) by 25% and an acidic shift of intracellular pH in the ischaemic heart. 3. In the ischaemic heart, OPC-18790, amrinone and dobutamine were applied at concentrations which increased LVdP/dt by about 60%. These compounds increased LVP by 15% to 30% and increased CPF by about 10%. Amrinone and dobutamine but not OPC-18790 increased heart rate. When these drugs produced the haemodynamic changes described above, amrinone and dobutamine reduced ATP and PCr, increased Pi and produced further intracellular acidosis, whereas, OPC-18790 did not change these parameters. 4. Cardiac pacing at 285 beats min-1 produced decreases in LVP, LVdP/dt and CPF by about 30%, 20%, 5%, respectively and an increase in Pi, decreases in PCr and ATP, and intracellular acidosis. 5. These results suggest that degradation of high energy phosphate compounds closely relates to increase in heart rate in the ischaemic heart. Positive inotropic agents without chronotropic action seem to be beneficial in support of the ischaemic heart.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7780644      PMCID: PMC1510324          DOI: 10.1111/j.1476-5381.1995.tb13318.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  16 in total

1.  Cardiotonic activity of amrinone--Win 40680 [5-amino-3,4'-bipyridine-6(1H)-one].

Authors:  A A Alousi; A E Farah; G Y Lesher; C J Opalka
Journal:  Circ Res       Date:  1979-11       Impact factor: 17.367

Review 2.  Dobutamine: a new synthetic cardioactive sympathetic amine.

Authors:  E H Sonnenblick; W H Frishman; T H LeJemtel
Journal:  N Engl J Med       Date:  1979-01-04       Impact factor: 91.245

3.  Effects of dobutamine on left ventricular performance, coronary dynamics, and distribution of cardiac output in conscious dogs.

Authors:  S F Vatner; R J McRitchie; E Braunwald
Journal:  J Clin Invest       Date:  1974-05       Impact factor: 14.808

4.  Involvement of cyclic AMP in the direct inotropic action of amrinone. Biochemical and functional evidence.

Authors:  P Honerjäger; M Schäfer-Korting; M Reiter
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1981-12       Impact factor: 3.000

5.  Effects of amrinone on experimental acute myocardial ischaemic injury.

Authors:  R E Rude; R A Kloner; P R Maroko; S Khuri; S Karaffa; L W DeBoer; E Braunwald
Journal:  Cardiovasc Res       Date:  1980-07       Impact factor: 10.787

6.  Myocardial metabolic and hemodynamic effects of dobutamine in heart failure complicating coronary artery disease.

Authors:  R G Pozen; R DiBianco; R J Katz; R Bortz; R J Myerburg; R D Fletcher
Journal:  Circulation       Date:  1981-06       Impact factor: 29.690

7.  Dobutamine: development of a new catecholamine to selectively increase cardiac contractility.

Authors:  R R Tuttle; J Mills
Journal:  Circ Res       Date:  1975-01       Impact factor: 17.367

8.  Mechanisms of ischemic myocardial cell damage assessed by phosphorus-31 nuclear magnetic resonance.

Authors:  J T Flaherty; M L Weisfeldt; B H Bulkley; T J Gardner; V L Gott; W E Jacobus
Journal:  Circulation       Date:  1982-03       Impact factor: 29.690

9.  Alpha and beta adrenergic effects of the stereoisomers of dobutamine.

Authors:  R R Ruffolo; T A Spradlin; G D Pollock; J E Waddell; P J Murphy
Journal:  J Pharmacol Exp Ther       Date:  1981-11       Impact factor: 4.030

10.  An in vitro quantitative analysis of the alpha adrenoceptor partial agonist activity of dobutamine and its relevance to inotropic selectivity.

Authors:  T P Kenakin
Journal:  J Pharmacol Exp Ther       Date:  1981-02       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.